{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:59:32Z","timestamp":1794013172428,"version":"4.8.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.transci.2022.103533","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T12:59:24Z","timestamp":1661777964000},"page":"103533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Acute and chronic pain management in patients with sickle cell disease in the modern era: a comprehensive review"],"prefix":"10.1016","volume":"61","author":[{"given":"Seda S.","family":"Tolu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla","family":"Van Doren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.transci.2022.103533_bib1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"86","author":"Modell","year":"2008","journal-title":"Bull World Health Organ"},{"issue":"7","key":"10.1016\/j.transci.2022.103533_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010\u20132050: modelling based on demographics, excess mortality, and interventions","volume":"10","author":"Piel","year":"2013","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.transci.2022.103533_bib3","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"15","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Prim"},{"issue":"10","key":"10.1016\/j.transci.2022.103533_bib4","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011783","article-title":"The natural history of sickle cell disease","volume":"3","author":"Serjeant","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"10.1016\/j.transci.2022.103533_bib5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/bloodadvances.2020002948","article-title":"A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy","volume":"5","author":"Badawy","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.transci.2022.103533_bib6","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.15169","article-title":"Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant","volume":"184","author":"Darbari","year":"2019","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.transci.2022.103533_bib7","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1056\/NEJMp2022125","article-title":"When actions speak louder than words\u2014racism and sickle cell disease","volume":"383","author":"Power-Hays","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.transci.2022.103533_bib8","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/ajcp\/26.10.1109","article-title":"The crisis in sickle cell anemia: hematologic studies","volume":"26","author":"Diggs","year":"1956","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.transci.2022.103533_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ajh.20336","article-title":"Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance","volume":"79","author":"Ballas","year":"2005","journal-title":"Am J Hematol"},{"issue":"18","key":"10.1016\/j.transci.2022.103533_bib10","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/bloodadvances.2018018382","article-title":"Increased acute care utilization in a prospective cohort of adults with sickle cell disease","volume":"2","author":"Lanzkron","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.transci.2022.103533_bib11","unstructured":"Ballas S.K., Darbari D.S. Review\/overview of pain in sickle cell disease. Cardeza Foundation for Hematologic Research. \u3008https:\/\/jdc.jefferson.edu\/cardeza_foundation\/54\u3009; 2020 [Accessed 3 March 2022]."},{"key":"10.1016\/j.transci.2022.103533_bib12","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1182\/blood-2013-05-498311","article-title":"Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies","volume":"122","author":"Manwani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.transci.2022.103533_bib13","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1172\/JCI119442","article-title":"Adhesive interactions of sickle erythrocytes with endothelium","volume":"99","author":"Hebbel","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.transci.2022.103533_bib14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/00062752-199603020-00003","article-title":"Molecular basis of sickle cell-endothelial cell interactions","volume":"3","author":"Wick","year":"1996","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.transci.2022.103533_bib15","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood.V98.6.1955","article-title":"P-selectin mediates the adhesion of sickle erythrocytes to the endothelium","volume":"98","author":"Matsui","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.transci.2022.103533_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1684\/ecn.2013.0328","article-title":"Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition","volume":"24","author":"Keikhaei","year":"2013","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.transci.2022.103533_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13430","article-title":"The vaso-occlusive pain crisis in sickle cell disease: definition, pathophysiology, and management","volume":"105","author":"Darbari","year":"2020","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.transci.2022.103533_bib18","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jpain.2016.12.016","article-title":"AAPT diagnostic criteria for chronic sickle cell disease pain","volume":"18","author":"Dampier","year":"2017","journal-title":"J Pain"},{"issue":"2","key":"10.1016\/j.transci.2022.103533_bib19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-148-2-200801150-00004","article-title":"Daily assessment of pain in adults with sickle cell disease","volume":"148","author":"Smith","year":"2008","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.transci.2022.103533_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11916-017-0629-5","article-title":"Neuropathic pain: central vs. peripheral mechanisms","volume":"21","author":"Meacham","year":"2017","journal-title":"Curr Pain Headache Rep"},{"issue":"12","key":"10.1016\/j.transci.2022.103533_bib21","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood-2010-12-327429","article-title":"Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease","volume":"118","author":"Hillery","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.transci.2022.103533_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216994","article-title":"Chronic pain in adults with sickle cell disease is associated with alterations in functional connectivity of the brain","volume":"14","author":"Karafin","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.transci.2022.103533_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nicl.2016.12.024","article-title":"Characterization of functional brain activity and connectivity using EEG and fMRI in patients with sickle cell disease","volume":"14","author":"Case","year":"2017","journal-title":"Neuroimage Clin"},{"issue":"4","key":"10.1016\/j.transci.2022.103533_bib24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/MPH.0000000000000532","article-title":"Clinical interpretation of quantitative sensory testing as a measure of pain sensitivity in patients with sickle cell disease","volume":"38","author":"Brandow","year":"2016","journal-title":"J Pedia Hematol Oncol"},{"issue":"6","key":"10.1016\/j.transci.2022.103533_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11916-017-0629-5","article-title":"Neuropathic pain: central vs. peripheral mechanisms","volume":"21","author":"Meacham","year":"2017","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"10.1016\/j.transci.2022.103533_bib26","doi-asserted-by":"crossref","first-page":"R104","DOI":"10.1152\/ajpregu.00021.2018","article-title":"Targeting pain at its source in sickle cell disease","volume":"315","author":"Gupta","year":"2018","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.transci.2022.103533_bib27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.neulet.2019.04.013","article-title":"Sensitization of nociceptors and dorsal horn neurons contributes to pain in sickle cell disease","volume":"705","author":"Uhelski","year":"2019","journal-title":"Neurosci Lett"},{"issue":"1","key":"10.1016\/j.transci.2022.103533_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/eujp.1999.0154","article-title":"Wind-up and the NMDA receptor complex from a clinical perspective","volume":"4","author":"Eide","year":"2000","journal-title":"Eur J Pain"},{"issue":"22","key":"10.1016\/j.transci.2022.103533_bib29","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2017-05-782003","article-title":"Targeting novel mechanisms of pain in sickle cell disease","volume":"130","author":"Tran","year":"2017","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.transci.2022.103533_bib30","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1056\/NEJM199111213252104","article-title":"Sickle cell disease as a cause of osteonecrosis of the femoral head","volume":"325","author":"Milner","year":"1991","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.transci.2022.103533_bib31","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1182\/bloodadvances.2017005256","article-title":"Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California","volume":"1","author":"Adesina","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.transci.2022.103533_bib32","first-page":"8","article-title":"Treatment for avascular necrosis of bone in people with sickle cell disease","author":"Mart\u00ed\u2010Carvajal","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.transci.2022.103533_bib33","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.arth.2020.04.014","article-title":"Total hip arthroplasty in patients with sickle cell disease: a comprehensive systematic review","volume":"35","author":"Fassihi","year":"2020","journal-title":"J Arthroplast"},{"issue":"4","key":"10.1016\/j.transci.2022.103533_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.arth.2014.10.035","article-title":"Does sickle cell disease increase risk of adverse outcomes following total hip and knee arthroplasty? A nationwide database study","volume":"30","author":"Perfetti","year":"2015","journal-title":"J Arthroplast"},{"issue":"16","key":"10.1016\/j.transci.2022.103533_bib35","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1182\/bloodadvances.2017005256","article-title":"Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California","volume":"1","author":"Oyebimpe","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.transci.2022.103533_bib36","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/03630269.2013.789968","article-title":"Leg ulcers in sickle cell disease: current patterns and practices","volume":"37","author":"Delaney","year":"2013","journal-title":"Hemoglobin"},{"issue":"4","key":"10.1016\/j.transci.2022.103533_bib37","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood.V74.4.1403.1403","article-title":"Leg ulcers in patients with sickle cell disease","volume":"74","author":"Koshy","year":"1989","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.transci.2022.103533_bib38","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/ajh.21838","article-title":"Leg ulcers in sickle cell disease","volume":"85","author":"Minniti","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2022.103533_bib39","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00129334-200410000-00010","article-title":"Leg ulcers in sickle cell disease","volume":"17","author":"Trent","year":"2004","journal-title":"Adv Ski Wound care"},{"issue":"1","key":"10.1016\/j.transci.2022.103533_bib40","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ajh.24134","article-title":"Critical Reviews: How we treat sickle cell patients with leg ulcers","volume":"91","author":"Minniti","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.transci.2022.103533_bib41","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/03630269.2013.789968","article-title":"Leg Ulcers in Sickle Cell Disease: Current Patterns and Practices","volume":"37","author":"Delaney","year":"2013","journal-title":"Hemoglobin"},{"issue":"3","key":"10.1016\/j.transci.2022.103533_bib42","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00277-021-04635-4","article-title":"Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease","volume":"101","author":"Tolu","year":"2022","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.transci.2022.103533_bib43","doi-asserted-by":"crossref","first-page":"E126","DOI":"10.1002\/ajh.26101","article-title":"The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease","volume":"96","author":"Minniti","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.transci.2022.103533_bib44","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/03630269509005824","article-title":"The Sickle Cell Painful Crisis in Adults: phases and objective signs","volume":"19","author":"Ballas","year":"1995","journal-title":"Hemoglobin"},{"issue":"5","key":"10.1016\/j.transci.2022.103533_bib45","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s11606-017-4289-2","article-title":"Do words matter? Stigmatizing language and the transmission of bias in the medical record","volume":"33","author":"P Goddu","year":"2018","journal-title":"J Gen Intern Med"},{"issue":"6","key":"10.1016\/j.transci.2022.103533_bib46","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ajh.23441","article-title":"Among emergency physicians, use of the term \u201cSickler\u201d is associated with negative attitudes toward people with sickle cell disease","volume":"88","author":"Glassberg","year":"2013","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.transci.2022.103533_bib47","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5055\/jom.2015.0273","article-title":"Daily home opioid use in adults with sickle cell disease: the PiSCES project","volume":"11","author":"Smith","year":"2015","journal-title":"J Opioid Manag"},{"issue":"2","key":"10.1016\/j.transci.2022.103533_bib48","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/jlme.12129","article-title":"Treating pain in sickle cell disease with opioids: clinical advances, ethical pitfalls","volume":"42","author":"Smith","year":"2014","journal-title":"J Law Med Ethics"},{"issue":"4","key":"10.1016\/j.transci.2022.103533_bib49","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11904-018-0398-8","article-title":"Federal response to the opioid crisis","volume":"15","author":"Johnson","year":"2018","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"6","key":"10.1016\/j.transci.2022.103533_bib50","doi-asserted-by":"crossref","first-page":"367","DOI":"10.7326\/M18-1243","article-title":"Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention\u2019s 2016 opioid guideline","volume":"169","author":"Bohnert","year":"2018","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.transci.2022.103533_bib51","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.4410","article-title":"Management of chronic pain in adults living with sickle cell disease in the era of the opioid epidemic: a qualitative study","volume":"2","author":"Sinha","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.transci.2022.103533_bib52","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood-2007-07-089144","article-title":"Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void","volume":"111","author":"Solomon","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.transci.2022.103533_bib53","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1093\/pm\/pnw074","article-title":"The opioid drug epidemic and sickle cell disease: guilt by association","volume":"17","author":"Ruta","year":"2016","journal-title":"Pain Med"},{"issue":"7","key":"10.1016\/j.transci.2022.103533_bib54","first-page":"533","article-title":"Depression in sickle cell disease","volume":"95","author":"Hasan","year":"2003","journal-title":"J Natl Med Assoc"},{"issue":"6","key":"10.1016\/j.transci.2022.103533_bib55","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2141.2005.05500.x","article-title":"Psychological complications in sickle cell disease","volume":"129","author":"Anie","year":"2005","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.transci.2022.103533_bib56","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"Jama"},{"issue":"19","key":"10.1016\/j.transci.2022.103533_bib57","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1182\/bloodadvances.2017007211","article-title":"Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review","volume":"1","author":"Sins","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.transci.2022.103533_bib58","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.annemergmed.2005.03.010","article-title":"Intravenous morphine at 0.1 mg\/kg is not effective for controlling severe acute pain in the majority of patients","volume":"46","author":"Bijur","year":"2005","journal-title":"Ann Emerg Med"},{"issue":"12","key":"10.1016\/j.transci.2022.103533_bib59","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain","volume":"4","author":"Brandow","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.transci.2022.103533_bib60","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/archinte.1991.00400070131017","article-title":"Intermittent injection vs patient-controlled analgesia for sickle cell crisis pain: comparison in patients in the emergency department","volume":"151","author":"Gonzalez","year":"1991","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.1016\/j.transci.2022.103533_bib61","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ajh.20944","article-title":"Patient\u2010controlled analgesia versus continuous infusion of morphine during vaso\u2010occlusive crisis in sickle cell disease, a randomized controlled trial","volume":"82","author":"van Beers","year":"2007","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.transci.2022.103533_bib62","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1182\/blood-2017-04-780635","article-title":"Extracellular fluid tonicity impacts sickle red blood cell deformability and adhesion","volume":"130","author":"Carden","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.transci.2022.103533_bib63","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7326\/M14-2559","article-title":"The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop","volume":"162","author":"Chou","year":"2015","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.transci.2022.103533_bib64","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/ajad.12605","article-title":"Ameliorative response to detoxification, psychotherapy, and medical management in patients maintained on opioids for pain","volume":"26","author":"Belkin","year":"2017","journal-title":"Am J Addict"},{"issue":"20","key":"10.1016\/j.transci.2022.103533_bib65","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1056\/NEJMra025411","article-title":"Opioid therapy for chronic pain","volume":"349","author":"Ballantyne","year":"2003","journal-title":"N Engl J Med"},{"issue":"20;2 2S","key":"10.1016\/j.transci.2022.103533_bib66","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.36076\/ppj.2017.s92","article-title":"Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines","volume":"20","author":"Manchikanti","year":"2017","journal-title":"Pain Physician"},{"key":"10.1016\/j.transci.2022.103533_bib67","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.amepre.2016.02.012","article-title":"Chronic opioid therapy and central sensitization in sickle cell disease","volume":"51","author":"Carroll","year":"2016","journal-title":"Am J Prev Med"},{"issue":"1","key":"10.1016\/j.transci.2022.103533_bib68","first-page":"553","article-title":"Neuropathic pain in sickle cell disease: measurement and management","author":"Alexander","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.transci.2022.103533_bib69","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.pmn.2017.07.003","article-title":"Management of sickle cell pain using pregabalin: a pilot study","volume":"18","author":"Schlaeger","year":"2017","journal-title":"Pain Manag Nurs"},{"issue":"3","key":"10.1016\/j.transci.2022.103533_bib70","article-title":"Cannabis-based medicines for chronic neuropathic pain in adults","volume":"3","author":"M\u00fccke","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.transci.2022.103533_bib71","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.2015.136523","article-title":"Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation","volume":"101","author":"Vincent","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.transci.2022.103533_bib72","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2010-01-260372","article-title":"Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids","volume":"116","author":"Kohli","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.transci.2022.103533_bib73","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1089\/can.2018.0001","article-title":"Marijuana use in adults living with sickle cell disease","volume":"3","author":"Roberts","year":"2018","journal-title":"Cannabis Cannabinoid Res"},{"issue":"4","key":"10.1016\/j.transci.2022.103533_bib74","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1590\/S0043-31442006000400004","article-title":"The prevalence of marijuana smoking in young adults with sickle cell disease: a longitudinal study","volume":"55","author":"Knight-Madden","year":"2006","journal-title":"West Indian Med J"},{"issue":"1","key":"10.1016\/j.transci.2022.103533_bib75","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2141.2005.05723.x","article-title":"Cannabis use in sickle cell disease: a questionnaire study","volume":"131","author":"Howard","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2022.103533_bib76","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/can.2017.0011","article-title":"The use of cannabis by patients with sickle cell disease increased the frequency of hospitalization due to Vaso-Occlusive Crises","volume":"2","author":"Ballas","year":"2017","journal-title":"Cannabis Cannabinoid Res"},{"issue":"3","key":"10.1016\/j.transci.2022.103533_bib77","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/can.2019.0036","article-title":"Daily cannabis users with sickle cell disease show fewer admissions than others with similar pain complaints","volume":"5","author":"Curtis","year":"2020","journal-title":"Cannabis Cannabinoid Res"},{"issue":"16","key":"10.1016\/j.transci.2022.103533_bib78","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1182\/bloodadvances.2020002325","article-title":"Medical marijuana certification for patients with sickle cell disease: a report of a single center experience","volume":"4","author":"Curtis","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.transci.2022.103533_bib79","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.10874","article-title":"Effect of inhaled cannabis for pain in adults with sickle cell disease: a randomized clinical trial","volume":"3","author":"Abrams","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.transci.2022.103533_bib80","article-title":"Ketamine for pain management","volume":"3","author":"Bell","year":"2018","journal-title":"Pain Rep"},{"key":"10.1016\/j.transci.2022.103533_bib81","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12887-015-0515-4","article-title":"Subanesthetic ketamine infusions for the treatment of children anda dolescents with chronic pain: a longitudinal study","volume":"15","author":"Sheehy","year":"2015","journal-title":"B MCPediatrics"},{"issue":"1","key":"10.1016\/j.transci.2022.103533_bib82","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1515\/sjpain-2017-0140","article-title":"Low dose ketamine versus morphine for acute severe vasoocclusive pain in children: a randomizedc ontrolled trial","volume":"18","author":"Lubega","year":"2018","journal-title":"Scand J Pain"},{"issue":"7","key":"10.1016\/j.transci.2022.103533_bib83","first-page":"1402","article-title":"Low-dose ketamine infusion for emergency department patients with severe pain","volume":"16","author":"Ahern","year":"2015","journal-title":"PainMed"},{"key":"10.1016\/j.transci.2022.103533_bib84","doi-asserted-by":"crossref","unstructured":"Sanacora G., Frye M.A., McDonald W., Mathew S., Turner M.S., Shatzberg A.F., et al.American Psychiatric Association (APA) council of research task force on novel biomarkers and treatments. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017; 74(4): 399\u2013405. https:\/\/ doi: \u300810.1001\/jamapsychiatry.2017.0080\u3009.","DOI":"10.1001\/jamapsychiatry.2017.0080"},{"issue":"21","key":"10.1016\/j.transci.2022.103533_bib85","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood.2020007645","article-title":"Fetal hemoglobin in sickle cell anemia","volume":"136","author":"Steinberg","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.transci.2022.103533_bib86","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2022.103533_bib87","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.transci.2022.103533_bib88","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of L-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2022.103533_bib89","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.transci.2022.103533_bib90","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050222002178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050222002178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:54:49Z","timestamp":1761468889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050222002178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1473050222002178"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2022.103533","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute and chronic pain management in patients with sickle cell disease in the modern era: a comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2022.103533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103533"}}